Exploratory analysis of a prognosis predictive formula for metastatic colorectal cancer treated with chemotherapy.

被引：0
|
作者：
Tanaka, Mamoru
Kusaba, Hitoshi
Mukaide, Satomi
Kishimoto, Junji
Kumagai, Hozumi
Makiyama, Akitaka
Shirakawa, Tsuyoshi
Oda, Hisanobu
Komoda, Masato
Mitsugi, Kenji
Akashi, Koichi
Baba, Eishi
机构：
[1] Kyushu Univ Hosp, Dept Hematol & Oncol, Fukuoka 812, Japan
[2] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 812, Japan
[3] Kyushu Univ Hosp, Dept Res & Dev Next Generat Med, Fac Med Sci, Fukuoka 812, Japan
[4] Japan Community Hlth Care Org Kyushu Hosp, Dept Hematol Oncol, Fukuoka, Japan
[5] Natl Hosp Org Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[7] Natl Hosp Org Kyushu Med Ctr, Dept Med Oncol, Fukuoka, Japan
[8] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan
[9] Kyushu Univ, Fac Med Sci, Dept Comprehens Clin Oncol, Fukuoka 812, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.757
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
757
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Primary tumor location as a prognostic and predictive factor in metastatic colorectal cancer (mCRC) treated with chemotherapy plus cetuximab: A retrospective analysis.
    Sagawa, Tamotsu
    Hamaguchi, Kyoko
    Sakurada, Akira
    Tamura, Fumito
    Hayashi, Tsuyoshi
    Fujikawa, Koshi
    Takahashi, Yasuo
    Sato, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] TUMOR BUDDING STATUS IN STAGE IV COLORECTAL CANCER: POTENTIAL IMPACT ON PROGNOSIS AND BENEFIT OF CHEMOTHERAPY.
    Nagata, K.
    Shinto, E.
    Kajiwara, Y.
    Yamadera, M.
    Mochizuki, S.
    Hase, K.
    Yamamoto, J.
    Ueno, H.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E455 - E456
  • [33] Immunosenescence in testicular cancer survivors treated with chemotherapy.
    Bourlon, Maria Teresa
    Velazquez, Hugo Eduardo
    Hinojosa, Juan
    Lima, Guadalupe
    Rios-Corzo, Ricardo
    Jimenez-Martinez, Karina
    Zarco-Letzel, Gabriela
    Llorente, Luis
    Atisha-Fregoso, Yemil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Proteinuria as a predictive factor in metastatic colorectal cancer patients treated with bevacizumab
    Uysal, Mukremin
    Bozcuk, Hakan Sat
    Goksu, Sema Sezgin
    Tatli, Ali Murat
    Arslan, Deniz
    Gunduz, Seyda
    Coskun, Hasan Senol
    Ozdogan, Mustafa
    Savas, Burhan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Emotional concerns in cancer survivors not treated with chemotherapy.
    Nikoomanesh, Tina
    Goldfarb, Melanie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03)
  • [36] Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Sarkar, S.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 154S - 154S
  • [37] Exploring the prognostic and predictive value of circulating tumor DNA in patients with advanced colorectal cancer and chemotherapy.
    Liu, Xiu
    Zhang, Xuan
    Ou, Kai
    Lu, Chelong
    Zheng, Dong
    Liu, Jun
    Xu, Qiang
    Yang, Lin
    CANCER RESEARCH, 2021, 81 (13)
  • [38] Chemotherapy of metastatic colorectal cancer
    deGramont, A
    Louvet, C
    Andre, T
    Tournigand, C
    Raymond, E
    Krulik, M
    PRESSE MEDICALE, 1996, 25 (35): : 1678 - 1682
  • [39] Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy.
    Grothe, W
    Arnold, D
    Peinert, S
    Voigt, W
    Loeffler, LM
    Siewczynski, R
    Steps, G
    Boehme, J
    Graeven, U
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 288S - 288S
  • [40] Chemotherapy in metastatic colorectal cancer
    Christopoulou A.
    Techniques in Coloproctology, 2004, 8 (Suppl 1) : S43 - S46
12345